<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="146154">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01713686</url>
  </required_header>
  <id_info>
    <org_study_id>ULT-129</org_study_id>
    <nct_id>NCT01713686</nct_id>
  </id_info>
  <brief_title>Evaluation of the Ulthera System for the Treatment of the Decolletage</brief_title>
  <official_title>Prospective, Multi-center, Pivotal Trial Evaluating the Safety and Effectiveness of the Ulthera® System for Improvement in Lines and Wrinkles of the Décolletage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ulthera, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ulthera, Inc</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is prospective, multi-center clinical trial.  Enrolled subjects will receive one
      Ulthera® treatment on the decolletage. Follow-up visits will occur at 90 and 180 days
      following treatment. Study images will be obtained pre-treatment, immediately
      post-treatment, and at each follow-up visit.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of Participants with a Reduction in Chest Wrinkles at 180 days Post Treatment</measure>
    <time_frame>180 days post treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessment of improvement, in a blinded fashion, using a Chest Wrinkle Scale at 180 days post-treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Aesthetic Improvement</measure>
    <time_frame>Participants will be followed to 180 days post-treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overall aesthetic improvement at each post treatment study visit will be compared to baseline will be assessed using the Global Aesthetic Improvement Scale (GAIS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Satisfaction</measure>
    <time_frame>Participants will be followed to180 days post-treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subject satisfaction will be measured at each follow-up visit using a Patient Satisfaction Questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with a Reduction in Chest Wrinkles at 90 days Post Treatment</measure>
    <time_frame>90 days post-treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessment of improvement, in a blinded fashion, using a Chest Wrinkle Scale at 90 days post-treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Chest Wrinkles</condition>
  <arm_group>
    <arm_group_label>Ulthera System Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ulthera System treatment of the decolletage</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ulthera System Treatment</intervention_name>
    <description>Focused ultrasound energy delivered below the surface of the skin</description>
    <arm_group_label>Ulthera System Treatment</arm_group_label>
    <other_name>Ultherapy™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female, aged 35 to 70 years.

          -  Subject in good health.

          -  Moderate to severe skin lines and wrinkles on the décolletage; grade of ≥4 on a chest
             wrinkle scale.

          -  Understands and accepts the obligation not to undergo any other procedures in the
             areas to be treated through the follow-up period.

          -  Willingness and ability to comply with protocol requirements.

          -  Subjects of childbearing potential must have a negative urine pregnancy test result
             and must not be lactating.

          -  Absence of physical conditions unacceptable to the investigator.

          -  Willingness and ability to provide written consent for study-required photography.

          -  Willingness and ability to provide written informed consent.

        Exclusion Criteria:

          -  Presence of an active systemic or local skin disease that may affect wound healing.

          -  Scarring in areas to be treated.

          -  Tattoos in the areas to be treated.

          -  Patients with ports or defibrillators.

          -  Any open wounds or lesions in the area.

          -  Active and severe inflammatory acne in the region to be treated.

          -  Patients who have a history with keloid formation or hypertrophic scarring.

          -  Inability to understand the protocol or to give informed consent.

          -  Retinoid, microdermabrasion, or prescription level glycolic acid treatments to the
             décolletage area within two weeks prior to study participation or during the study.

          -  Marked décolletage asymmetry, ptosis, excessive dermatochalasis, deep dermal
             scarring, or thick sebaceous skin.

          -  History of chronic drug or alcohol abuse.

          -  History of autoimmune disease.

          -  Concurrent therapy that would interfere with the evaluation of the safety or
             effectiveness of the study device.

          -  Subjects who anticipate the need for surgery or overnight hospitalization during the
             study.

          -  Subjects who have a history of poor cooperation, noncompliance with medical
             treatment, or unreliability.

          -  Concurrent enrollment in any study involving the use of investigational devices or
             drugs.

          -  Current smoker or history of smoking in the last one year.

          -  History of using the following prescription medications:

               1. Topical Retinoids to the area within the past two weeks;

               2. Antiplatelet agents/anticoagulants (Coumadin, Heparin, Plavix).

               3. Psychiatric drugs that would impair the subject from understanding the protocol
                  requirements or understanding and signing the informed consent.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitchel P Goldman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermatology Cosmetic Laser Medical  Associates of La Jolla, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Laser Skin and Surgery Center of Northern California</name>
      <address>
        <city>Sacremento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Cosmetic Laser Medical Associates of La Jolla, Inc.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denova Research</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Research Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 9, 2013</lastchanged_date>
  <firstreceived_date>October 22, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ulthera® System</keyword>
  <keyword>Ultherapy™ Treatment</keyword>
  <keyword>Ulthera, Inc.</keyword>
  <keyword>Micro-focused Ultrasound with Visualization (MFU-V)</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
